BioNTech SE (BNTX)

NMS – Real vaqt narxi. Valyuta: USD

93.66

+0.32 (0.34%)

Yopilishda: May 12, 2026, 4:00 PM EDT

07.05.2026

BioNTech Announces New ADS Repurchase Program

MAINZ, Germany, May 7, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program”), under which the Company may repurchase American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, for an aggregate amount of up to $1.0 billion. Repurchases under the Program may be made until and including May 6, 2027.

06.05.2026

BioNTech Q3 Earnings Review: Getting Into The Weeds With Bewildering Oncology Plans

BioNTech SE is downgraded to Sell due to declining COVID vaccine revenues, leadership exits, and pipeline uncertainty. BNTX faces €531.9m Q1 net loss, expects €2–3bn 2026 revenues, and plans €1bn share buyback amid €16.8bn cash reserves. Major staff cuts and site exits are underway, targeting €500m annual savings to support the oncology pivot.

06.05.2026

Germany says vaccine supply secure despite BioNTech production loss

A German government spokesperson said on ‌Wednesday that the loss of BioNTech vaccine production in the country ⁠can be offset by other companies.

05.05.2026

BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript

05.05.2026

BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape

Shares of BioNTech SE (NASDAQ:BNTX) are trading lower on Tuesday as the company reported mixed first-quarter financial results.

05.05.2026

BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

The company said it would exit operations at some manufacturing plants in Germany and Singapore, as well as sites it acquired as part of its CureVac takeover.

05.05.2026

BioNTech to close sites in Germany, Singapore affecting 1,860 staff

Germany's BioNTech said on Tuesday it would close sites affecting up to 1,860 jobs and buy back up to $1 billion worth of its shares, following the announcement ‌of two co-founders quitting the COVID-19 vaccine maker.

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

BioNTech SE (Nasdaq: BNTX) today reported financial results for the three months ended March 31, 2026 and provided an update on its corporate progress.

11.04.2026

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

BioNTech today announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan in HER2+ endometrial cancer.

24.03.2026

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

MAINZ, Germany, March 24, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data from its diversified portfolio in the field of lung cancer at the European Lung Cancer Congress (“ELCC”) held in Copenhagen, Denmark, from March 25-28, 2026. The data updates covered in both oral and poster presentations highlight progress across late-stage immunomodulator candidates pumitamig and gotistobart, as well as antibody-drug conjugate (“ADC”) programs, across various lung cancer subtypes and lines of treatment. BioNTech's clinical portfolio encompasses both monotherapies and combinations with standard of care treatments, as well as novel-novel combination regimens aimed at delivering differentiated therapeutic profiles for the treatment of patients with lung cancer across all stages of the disease.

BioNTech SE (BNTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

BioNTech SE (BNTX)

BioNTech Announces New ADS Repurchase Program

BioNTech Q3 Earnings Review: Getting Into The Weeds With Bewildering Oncology Plans

Germany says vaccine supply secure despite BioNTech production loss

BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript

BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape

BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

BioNTech to close sites in Germany, Singapore affecting 1,860 staff

Videolar

Press-relizlar

BioNTech Announces New ADS Repurchase Program

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

BioNTech Announces New ADS Repurchase Program

BioNTech Q3 Earnings Review: Getting Into The Weeds With Bewildering Oncology Plans

Germany says vaccine supply secure despite BioNTech production loss

BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript

BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape

BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

BioNTech to close sites in Germany, Singapore affecting 1,860 staff

Videolar

Press-relizlar

BioNTech Announces New ADS Repurchase Program

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

Search stocks

BioNTech SE (BNTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

BioNTech SE (BNTX)

BioNTech Announces New ADS Repurchase Program

BioNTech Q3 Earnings Review: Getting Into The Weeds With Bewildering Oncology Plans

Germany says vaccine supply secure despite BioNTech production loss

BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript

BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape

BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

BioNTech to close sites in Germany, Singapore affecting 1,860 staff

Videolar

Press-relizlar

BioNTech Announces New ADS Repurchase Program

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

BioNTech Announces New ADS Repurchase Program

BioNTech Q3 Earnings Review: Getting Into The Weeds With Bewildering Oncology Plans

Germany says vaccine supply secure despite BioNTech production loss

BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript

BioNTech Slides As Vaccine Sales Drop, Restructuring Plan Takes Shape

BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

BioNTech to close sites in Germany, Singapore affecting 1,860 staff

Videolar

Press-relizlar

BioNTech Announces New ADS Repurchase Program

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer